Peer Re­view: KSQ woos Beni Wolf from Blue­print with CRISPR plat­form; As­traZeneca ex­ec jumps to CNS biotech spun out of Take­da

→ Af­ter four years at Blue­print Med­i­cines, Beni Wolf is hop­ping over to Cam­bridge, Mass­a­chu­setts-based KSQ Ther­a­peu­tics as chief med­ical of­fi­cer, as it pre­pares to take its lead ex­per­i­men­tal drug in­to the clin­ic in 2020. “KSQ’s CRISPRomics ap­proach holds tremen­dous po­ten­tial for de­vel­op­ing high-im­pact can­cer med­i­cines,” Wolf said in a state­ment.

→ An em­bat­tled Mer­ri­mack $MACK — hav­ing been forced to aban­don its clin­i­cal ex­per­i­men­tal drugs af­ter a se­ries of set­backs and job cuts — last week lost its chief med­ical of­fi­cer. In a fil­ing, the com­pa­ny said CMO Ser­gio San­til­lana had ten­dered his res­ig­na­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER